Optimal use of pegvisomant in acromegaly: are we getting there?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

14 citing papers in PubMed, 23 citations in OpenAlex.

1. Combination therapy of pasireotide and pegvisomant for aggressive acromegaly with an immature PIT1-lineage PitNET.Endocrinology, diabetes & metabolism case reports · 2026
   Article
2. Acromegaly and Bone: An Update.Endocrinology and metabolism (Seoul, Korea) · 2023
   Review
3. Modern approach to resistant acromegaly.Endocrine · 2023
   Article
4. Effects of Anterior Pituitary Adenomas' Hormones on Glucose Metabolism and Its Clinical Implications.Diabetes, metabolic syndrome and obesity : targets and therapy · 2023
   Review
5. Extending lifespan by modulating the growth hormone/insulin-like growth factor-1 axis: coming of age.Pituitary · 2021
   Review
6. Multidisciplinary management of acromegaly: A consensus.Reviews in endocrine & metabolic disorders · 2020
   Review
7. Fabula (non) acta est….Endocrine.Endocrine · 2018
   Article
8. Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly.Pituitary · 2018
   Article
9. How to improve effectiveness of pegvisomant treatment in acromegalic patients.Journal of endocrinological investigation · 2018
   Observational
10. Prevalence of morphometric vertebral fractures in "difficult" patients with acromegaly with different biochemical outcomes after multimodal treatment.Endocrine · 2018
    Article
11. Pegvisomant in acromegaly: an update.Journal of endocrinological investigation · 2017
    Review
12. Daily life reflections of acromegaly guidelines.Journal of endocrinological investigation · 2017
    Article
13. Prediction of therapy response in acromegalic patients under pegvisomant therapy within the German ACROSTUDY cohort.Pituitary · 2015
    Article
14. Medical treatment of acromegaly in pregnancy, highlights on new reports.Endocrine · 2015
    Article

Corrections and comments

• Comment on
  ACROSTUDY: the Italian experience.2015

Authors and funding

1 author at 1 institution in 2 countries.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as